img

Global Human Genetically Engineered Vaccine Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Human Genetically Engineered Vaccine Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Human Genetically Engineered Vaccine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Genetically Engineered Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hepatitis E and Human Papillomavirus (HPV) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Human Genetically Engineered Vaccine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Human Genetically Engineered Vaccine key manufacturers include Pfizer, Merck, GSK, Beijing Wantai Biological Pharmacy Enterprise CO.,LTD., Walvax Biotechnology Co., Ltd., Bharat Biotech, Chengdu Kanghua Biological Products Co., Ltd., South China Vaccine Corporation Limited and Beijing Health Guard Biotechnology Inc., etc. Pfizer, Merck, GSK are top 3 players and held % sales share in total in 2022.
Human Genetically Engineered Vaccine can be divided into Genetic Recombinant Vaccine, Recombinant Subunit Vaccines and Genetic Vaccine,, etc. Genetic Recombinant Vaccine is the mainstream product in the market, accounting for % sales share globally in 2022.
Human Genetically Engineered Vaccine is widely used in various fields, such as Hepatitis E, Human Papillomavirus (HPV), Rotavirus and Others, etc. Hepatitis E provides greatest supports to the Human Genetically Engineered Vaccine industry development. In 2022, global % sales of Human Genetically Engineered Vaccine went into Hepatitis E filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Genetically Engineered Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Pfizer
Merck
GSK
Beijing Wantai Biological Pharmacy Enterprise CO.,LTD.
Walvax Biotechnology Co., Ltd.
Bharat Biotech
Chengdu Kanghua Biological Products Co., Ltd.
South China Vaccine Corporation Limited
Beijing Health Guard Biotechnology Inc.
CSL Limited
Emergent BioSolutions
Sanofi Pasteur
Serum Institute
Segment by Type
Genetic Recombinant Vaccine
Recombinant Subunit Vaccines
Genetic Vaccine

Segment by Application


Hepatitis E
Human Papillomavirus (HPV)
Rotavirus
Others

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Human Genetically Engineered Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Human Genetically Engineered Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Human Genetically Engineered Vaccine industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Human Genetically Engineered Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Human Genetically Engineered Vaccine introduction, etc. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Human Genetically Engineered Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Human Genetically Engineered Vaccine Market Overview
1.1 Human Genetically Engineered Vaccine Product Overview
1.2 Human Genetically Engineered Vaccine Market Segment by Type
1.2.1 Genetic Recombinant Vaccine
1.2.2 Recombinant Subunit Vaccines
1.2.3 Genetic Vaccine
1.3 Global Human Genetically Engineered Vaccine Market Size by Type
1.3.1 Global Human Genetically Engineered Vaccine Market Size Overview by Type (2024-2034)
1.3.2 Global Human Genetically Engineered Vaccine Historic Market Size Review by Type (2024-2024)
1.3.3 Global Human Genetically Engineered Vaccine Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Human Genetically Engineered Vaccine Sales Breakdown by Type (2024-2024)
1.4.2 Europe Human Genetically Engineered Vaccine Sales Breakdown by Type (2024-2024)
1.4.3 Asia-Pacific Human Genetically Engineered Vaccine Sales Breakdown by Type (2024-2024)
1.4.4 Latin America Human Genetically Engineered Vaccine Sales Breakdown by Type (2024-2024)
1.4.5 Middle East and Africa Human Genetically Engineered Vaccine Sales Breakdown by Type (2024-2024)
2 Global Human Genetically Engineered Vaccine Market Competition by Company
2.1 Global Top Players by Human Genetically Engineered Vaccine Sales (2024-2024)
2.2 Global Top Players by Human Genetically Engineered Vaccine Revenue (2024-2024)
2.3 Global Top Players by Human Genetically Engineered Vaccine Price (2024-2024)
2.4 Global Top Manufacturers Human Genetically Engineered Vaccine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Human Genetically Engineered Vaccine Market Competitive Situation and Trends
2.5.1 Human Genetically Engineered Vaccine Market Concentration Rate (2024-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Human Genetically Engineered Vaccine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Genetically Engineered Vaccine as of 2022)
2.7 Date of Key Manufacturers Enter into Human Genetically Engineered Vaccine Market
2.8 Key Manufacturers Human Genetically Engineered Vaccine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Human Genetically Engineered Vaccine Status and Outlook by Region
3.1 Global Human Genetically Engineered Vaccine Market Size and CAGR by Region: 2024 VS 2022 VS 2034
3.2 Global Human Genetically Engineered Vaccine Historic Market Size by Region
3.2.1 Global Human Genetically Engineered Vaccine Sales in Volume by Region (2024-2024)
3.2.2 Global Human Genetically Engineered Vaccine Sales in Value by Region (2024-2024)
3.2.3 Global Human Genetically Engineered Vaccine Sales (Volume & Value) Price and Gross Margin (2024-2024)
3.3 Global Human Genetically Engineered Vaccine Forecasted Market Size by Region
3.3.1 Global Human Genetically Engineered Vaccine Sales in Volume by Region (2024-2034)
3.3.2 Global Human Genetically Engineered Vaccine Sales in Value by Region (2024-2034)
3.3.3 Global Human Genetically Engineered Vaccine Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Human Genetically Engineered Vaccine by Application
4.1 Human Genetically Engineered Vaccine Market Segment by Application
4.1.1 Hepatitis E
4.1.2 Human Papillomavirus (HPV)
4.1.3 Rotavirus
4.1.4 Others
4.2 Global Human Genetically Engineered Vaccine Market Size by Application
4.2.1 Global Human Genetically Engineered Vaccine Market Size Overview by Application (2024-2034)
4.2.2 Global Human Genetically Engineered Vaccine Historic Market Size Review by Application (2024-2024)
4.2.3 Global Human Genetically Engineered Vaccine Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Human Genetically Engineered Vaccine Sales Breakdown by Application (2024-2024)
4.3.2 Europe Human Genetically Engineered Vaccine Sales Breakdown by Application (2024-2024)
4.3.3 Asia-Pacific Human Genetically Engineered Vaccine Sales Breakdown by Application (2024-2024)
4.3.4 Latin America Human Genetically Engineered Vaccine Sales Breakdown by Application (2024-2024)
4.3.5 Middle East and Africa Human Genetically Engineered Vaccine Sales Breakdown by Application (2024-2024)
5 North America Human Genetically Engineered Vaccine by Country
5.1 North America Human Genetically Engineered Vaccine Historic Market Size by Country
5.1.1 North America Human Genetically Engineered Vaccine Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
5.1.2 North America Human Genetically Engineered Vaccine Sales in Volume by Country (2024-2024)
5.1.3 North America Human Genetically Engineered Vaccine Sales in Value by Country (2024-2024)
5.2 North America Human Genetically Engineered Vaccine Forecasted Market Size by Country
5.2.1 North America Human Genetically Engineered Vaccine Sales in Volume by Country (2024-2034)
5.2.2 North America Human Genetically Engineered Vaccine Sales in Value by Country (2024-2034)
6 Europe Human Genetically Engineered Vaccine by Country
6.1 Europe Human Genetically Engineered Vaccine Historic Market Size by Country
6.1.1 Europe Human Genetically Engineered Vaccine Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
6.1.2 Europe Human Genetically Engineered Vaccine Sales in Volume by Country (2024-2024)
6.1.3 Europe Human Genetically Engineered Vaccine Sales in Value by Country (2024-2024)
6.2 Europe Human Genetically Engineered Vaccine Forecasted Market Size by Country
6.2.1 Europe Human Genetically Engineered Vaccine Sales in Volume by Country (2024-2034)
6.2.2 Europe Human Genetically Engineered Vaccine Sales in Value by Country (2024-2034)
7 Asia-Pacific Human Genetically Engineered Vaccine by Region
7.1 Asia-Pacific Human Genetically Engineered Vaccine Historic Market Size by Region
7.1.1 Asia-Pacific Human Genetically Engineered Vaccine Market Size Growth Rate (CAGR) by Region: 2024 VS 2022 VS 2034
7.1.2 Asia-Pacific Human Genetically Engineered Vaccine Sales in Volume by Region (2024-2024)
7.1.3 Asia-Pacific Human Genetically Engineered Vaccine Sales in Value by Region (2024-2024)
7.2 Asia-Pacific Human Genetically Engineered Vaccine Forecasted Market Size by Region
7.2.1 Asia-Pacific Human Genetically Engineered Vaccine Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Human Genetically Engineered Vaccine Sales in Value by Region (2024-2034)
8 Latin America Human Genetically Engineered Vaccine by Country
8.1 Latin America Human Genetically Engineered Vaccine Historic Market Size by Country
8.1.1 Latin America Human Genetically Engineered Vaccine Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
8.1.2 Latin America Human Genetically Engineered Vaccine Sales in Volume by Country (2024-2024)
8.1.3 Latin America Human Genetically Engineered Vaccine Sales in Value by Country (2024-2024)
8.2 Latin America Human Genetically Engineered Vaccine Forecasted Market Size by Country
8.2.1 Latin America Human Genetically Engineered Vaccine Sales in Volume by Country (2024-2034)
8.2.2 Latin America Human Genetically Engineered Vaccine Sales in Value by Country (2024-2034)
9 Middle East and Africa Human Genetically Engineered Vaccine by Country
9.1 Middle East and Africa Human Genetically Engineered Vaccine Historic Market Size by Country
9.1.1 Middle East and Africa Human Genetically Engineered Vaccine Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
9.1.2 Middle East and Africa Human Genetically Engineered Vaccine Sales in Volume by Country (2024-2024)
9.1.3 Middle East and Africa Human Genetically Engineered Vaccine Sales in Value by Country (2024-2024)
9.2 Middle East and Africa Human Genetically Engineered Vaccine Forecasted Market Size by Country
9.2.1 Middle East and Africa Human Genetically Engineered Vaccine Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Human Genetically Engineered Vaccine Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Introduction and Business Overview
10.1.3 Pfizer Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.1.4 Pfizer Human Genetically Engineered Vaccine Products Offered
10.1.5 Pfizer Recent Development
10.2 Merck
10.2.1 Merck Company Information
10.2.2 Merck Introduction and Business Overview
10.2.3 Merck Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.2.4 Merck Human Genetically Engineered Vaccine Products Offered
10.2.5 Merck Recent Development
10.3 GSK
10.3.1 GSK Company Information
10.3.2 GSK Introduction and Business Overview
10.3.3 GSK Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.3.4 GSK Human Genetically Engineered Vaccine Products Offered
10.3.5 GSK Recent Development
10.4 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD.
10.4.1 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Company Information
10.4.2 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Introduction and Business Overview
10.4.3 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.4.4 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Products Offered
10.4.5 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Recent Development
10.5 Walvax Biotechnology Co., Ltd.
10.5.1 Walvax Biotechnology Co., Ltd. Company Information
10.5.2 Walvax Biotechnology Co., Ltd. Introduction and Business Overview
10.5.3 Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.5.4 Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Products Offered
10.5.5 Walvax Biotechnology Co., Ltd. Recent Development
10.6 Bharat Biotech
10.6.1 Bharat Biotech Company Information
10.6.2 Bharat Biotech Introduction and Business Overview
10.6.3 Bharat Biotech Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.6.4 Bharat Biotech Human Genetically Engineered Vaccine Products Offered
10.6.5 Bharat Biotech Recent Development
10.7 Chengdu Kanghua Biological Products Co., Ltd.
10.7.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
10.7.2 Chengdu Kanghua Biological Products Co., Ltd. Introduction and Business Overview
10.7.3 Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.7.4 Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Products Offered
10.7.5 Chengdu Kanghua Biological Products Co., Ltd. Recent Development
10.8 South China Vaccine Corporation Limited
10.8.1 South China Vaccine Corporation Limited Company Information
10.8.2 South China Vaccine Corporation Limited Introduction and Business Overview
10.8.3 South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.8.4 South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Products Offered
10.8.5 South China Vaccine Corporation Limited Recent Development
10.9 Beijing Health Guard Biotechnology Inc.
10.9.1 Beijing Health Guard Biotechnology Inc. Company Information
10.9.2 Beijing Health Guard Biotechnology Inc. Introduction and Business Overview
10.9.3 Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.9.4 Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Products Offered
10.9.5 Beijing Health Guard Biotechnology Inc. Recent Development
10.10 CSL Limited
10.10.1 CSL Limited Company Information
10.10.2 CSL Limited Introduction and Business Overview
10.10.3 CSL Limited Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.10.4 CSL Limited Human Genetically Engineered Vaccine Products Offered
10.10.5 CSL Limited Recent Development
10.11 Emergent BioSolutions
10.11.1 Emergent BioSolutions Company Information
10.11.2 Emergent BioSolutions Introduction and Business Overview
10.11.3 Emergent BioSolutions Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.11.4 Emergent BioSolutions Human Genetically Engineered Vaccine Products Offered
10.11.5 Emergent BioSolutions Recent Development
10.12 Sanofi Pasteur
10.12.1 Sanofi Pasteur Company Information
10.12.2 Sanofi Pasteur Introduction and Business Overview
10.12.3 Sanofi Pasteur Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.12.4 Sanofi Pasteur Human Genetically Engineered Vaccine Products Offered
10.12.5 Sanofi Pasteur Recent Development
10.13 Serum Institute
10.13.1 Serum Institute Company Information
10.13.2 Serum Institute Introduction and Business Overview
10.13.3 Serum Institute Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.13.4 Serum Institute Human Genetically Engineered Vaccine Products Offered
10.13.5 Serum Institute Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Human Genetically Engineered Vaccine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Human Genetically Engineered Vaccine Industrial Chain Analysis
11.4 Human Genetically Engineered Vaccine Market Dynamics
11.4.1 Human Genetically Engineered Vaccine Industry Trends
11.4.2 Human Genetically Engineered Vaccine Market Drivers
11.4.3 Human Genetically Engineered Vaccine Market Challenges
11.4.4 Human Genetically Engineered Vaccine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Human Genetically Engineered Vaccine Distributors
12.3 Human Genetically Engineered Vaccine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Genetic Recombinant Vaccine
Table 2. Major Company of Recombinant Subunit Vaccines
Table 3. Major Company of Genetic Vaccine
Table 4. Global Human Genetically Engineered Vaccine Sales by Type 2024 VS 2022 VS 2034 (US$ Million)
Table 5. Global Human Genetically Engineered Vaccine Sales by Type (2024-2024) & (K Units)
Table 6. Global Human Genetically Engineered Vaccine Sales Market Share in Volume by Type (2024-2024)
Table 7. Global Human Genetically Engineered Vaccine Sales by Type (2024-2024) & (US& Million)
Table 8. Global Human Genetically Engineered Vaccine Market Share in Value by Type (2024-2024)
Table 9. Global Human Genetically Engineered Vaccine Price by Type (2024-2024) & (US$/Unit)
Table 10. Global Human Genetically Engineered Vaccine Sales by Type (2024-2034) & (K Units)
Table 11. Global Human Genetically Engineered Vaccine Sales Market Share in Volume by Type (2024-2034)
Table 12. Global Human Genetically Engineered Vaccine Sales by Type (2024-2034) & (US$ Million)
Table 13. Global Human Genetically Engineered Vaccine Sales Market Share in Value by Type (2024-2034)
Table 14. Global Human Genetically Engineered Vaccine Price by Type (2024-2034) & (US$/Unit)
Table 15. North America Human Genetically Engineered Vaccine Sales by Type (2024-2024) & (K Units)
Table 16. North America Human Genetically Engineered Vaccine Sales by Type (2024-2024) & (US$ Million)
Table 17. Europe Human Genetically Engineered Vaccine Sales (K Units) by Type (2024-2024)
Table 18. Europe Human Genetically Engineered Vaccine Sales by Type (2024-2024) & (US$ Million)
Table 19. Asia-Pacific Human Genetically Engineered Vaccine Sales (K Units) by Type (2024-2024)
Table 20. Asia-Pacific Human Genetically Engineered Vaccine Sales by Type (2024-2024) & (US$ Million)
Table 21. Latin America Human Genetically Engineered Vaccine Sales (K Units) by Type (2024-2024)
Table 22. Latin America Human Genetically Engineered Vaccine Sales by Type (2024-2024) & (US$ Million)
Table 23. Middle East and Africa Human Genetically Engineered Vaccine Sales (K Units) by Type (2024-2024)
Table 24. Middle East and Africa Human Genetically Engineered Vaccine Sales by Type (2024-2024) & (US$ Million)
Table 25. Global Human Genetically Engineered Vaccine Sales by Company (2024-2024) & (K Units)
Table 26. Global Human Genetically Engineered Vaccine Sales Share by Company (2024-2024)
Table 27. Global Human Genetically Engineered Vaccine Revenue by Company (2024-2024) & (US$ Million)
Table 28. Global Human Genetically Engineered Vaccine Revenue Share by Company (2024-2024)
Table 29. Global Market Human Genetically Engineered Vaccine Price by Company (2024-2024) & (US$/Unit)
Table 30. Global Human Genetically Engineered Vaccine Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 31. Global Human Genetically Engineered Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 32. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Genetically Engineered Vaccine as of 2022)
Table 33. Date of Key Manufacturers Enter into Human Genetically Engineered Vaccine Market
Table 34. Key Manufacturers Human Genetically Engineered Vaccine Product Type
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Human Genetically Engineered Vaccine Market Size Comparison by Region (US$ Million): 2024 VS 2022 VS 2034
Table 37. Global Human Genetically Engineered Vaccine Sales by Region (2024-2024) & (K Units)
Table 38. Global Human Genetically Engineered Vaccine Sales Market Share in Volume by Region (2024-2024)
Table 39. Global Human Genetically Engineered Vaccine Sales by Region (2024-2024) & (US$ Million)
Table 40. Global Human Genetically Engineered Vaccine Sales Market Share in Value by Region (2024-2024)
Table 41. Global Human Genetically Engineered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 42. Global Human Genetically Engineered Vaccine Sales by Region (2024-2034) & (K Units)
Table 43. Global Human Genetically Engineered Vaccine Sales Market Share in Volume by Region (2024-2034)
Table 44. Global Human Genetically Engineered Vaccine Sales by Region (2024-2034) & (US$ Million)
Table 45. Global Human Genetically Engineered Vaccine Sales Market Share in Value by Region (2024-2034)
Table 46. Global Human Genetically Engineered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2034)
Table 47. Global Human Genetically Engineered Vaccine Sales by Application: 2024 VS 2022 VS 2034 (US$ Million)
Table 48. Global Human Genetically Engineered Vaccine Sales by Application (2024-2024) & (K Units)
Table 49. Global Human Genetically Engineered Vaccine Sales Market Share in Volume by Application (2024-2024)
Table 50. Global Human Genetically Engineered Vaccine Sales by Application (2024-2024) & (US$ Million)
Table 51. Global Human Genetically Engineered Vaccine Sales Market Share in Value by Application (2024-2024)
Table 52. Global Human Genetically Engineered Vaccine Price by Application (2024-2024) & (US$/Unit)
Table 53. Global Human Genetically Engineered Vaccine Sales by Application (2024-2034) & (K Units)
Table 54. Global Human Genetically Engineered Vaccine Sales Market Share in Volume by Application (2024-2034)
Table 55. Global Human Genetically Engineered Vaccine Sales by Application (2024-2034) & (US$ Million)
Table 56. Global Human Genetically Engineered Vaccine Sales Market Share in Value by Application (2024-2034)
Table 57. Global Human Genetically Engineered Vaccine Price by Application (2024-2034) & (US$/Unit)
Table 58. North America Human Genetically Engineered Vaccine Sales by Application (2024-2024) (K Units)
Table 59. North America Human Genetically Engineered Vaccine Sales by Application (2024-2024) & (US$ Million)
Table 60. Europe Human Genetically Engineered Vaccine Sales by Application (2024-2024) (K Units)
Table 61. Europe Human Genetically Engineered Vaccine Sales by Application (2024-2024) & (US$ Million)
Table 62. Asia-Pacific Human Genetically Engineered Vaccine Sales by Application (2024-2024) (K Units)
Table 63. Asia-Pacific Human Genetically Engineered Vaccine Sales by Application (2024-2024) & (US$ Million)
Table 64. Latin America Human Genetically Engineered Vaccine Sales by Application (2024-2024) (K Units)
Table 65. Latin America Human Genetically Engineered Vaccine Sales by Application (2024-2024) & (US$ Million)
Table 66. Middle East and Africa Human Genetically Engineered Vaccine Sales by Application (2024-2024) (K Units)
Table 67. Middle East and Africa Human Genetically Engineered Vaccine Sales by Application (2024-2024) & (US$ Million)
Table 68. North America Human Genetically Engineered Vaccine Sales by Country (2024-2024) & (K Units)
Table 69. North America Human Genetically Engineered Vaccine Sales Market Share in Volume by Country (2024-2024)
Table 70. North America Human Genetically Engineered Vaccine Sales by Country (2024-2024) & (US$ Million)
Table 71. North America Human Genetically Engineered Vaccine Sales Market Share in Value by Country (2024-2024)
Table 72. North America Human Genetically Engineered Vaccine Sales by Country (2024-2034) & (K Units)
Table 73. North America Human Genetically Engineered Vaccine Sales Market Share in Volume by Country (2024-2034)
Table 74. North America Human Genetically Engineered Vaccine Sales by Country (2024-2034) & (US$ Million)
Table 75. North America Human Genetically Engineered Vaccine Sales Market Share in Value by Country (2024-2034)
Table 76. Europe Human Genetically Engineered Vaccine Sales by Country (2024-2024) & (K Units)
Table 77. Europe Human Genetically Engineered Vaccine Sales Market Share in Volume by Country (2024-2024)
Table 78. Europe Human Genetically Engineered Vaccine Sales by Country (2024-2024) & (US$ Million)
Table 79. Europe Human Genetically Engineered Vaccine Sales Market Share in Value by Country (2024-2024)
Table 80. Europe Human Genetically Engineered Vaccine Sales by Country (2024-2034) & (K Units)
Table 81. Europe Human Genetically Engineered Vaccine Sales Market Share in Volume by Country (2024-2034)
Table 82. Europe Human Genetically Engineered Vaccine Sales by Country (2024-2034) & (US$ Million)
Table 83. Europe Human Genetically Engineered Vaccine Sales Market Share in Value by Country (2024-2034)
Table 84. Asia-Pacific Human Genetically Engineered Vaccine Sales by Region (2024-2024) & (K Units)
Table 85. Asia-Pacific Human Genetically Engineered Vaccine Sales Market Share in Volume by Region (2024-2024)
Table 86. Asia-Pacific Human Genetically Engineered Vaccine Sales by Region (2024-2024) & (US$ Million)
Table 87. Asia-Pacific Human Genetically Engineered Vaccine Sales Market Share in Value by Region (2024-2024)
Table 88. Asia-Pacific Human Genetically Engineered Vaccine Sales by Region (2024-2034) & (K Units)
Table 89. Asia-Pacific Human Genetically Engineered Vaccine Sales Market Share in Volume by Region (2024-2034)
Table 90. Asia-Pacific Human Genetically Engineered Vaccine Sales by Region (2024-2034) & (US$ Million)
Table 91. Asia-Pacific Human Genetically Engineered Vaccine Sales Market Share in Value by Region (2024-2034)
Table 92. Latin America Human Genetically Engineered Vaccine Sales by Country (2024-2024) & (K Units)
Table 93. Latin America Human Genetically Engineered Vaccine Sales Market Share in Volume by Country (2024-2024)
Table 94. Latin America Human Genetically Engineered Vaccine Sales by Country (2024-2024) & (US$ Million)
Table 95. Latin America Human Genetically Engineered Vaccine Sales Market Share in Value by Country (2024-2024)
Table 96. Latin America Human Genetically Engineered Vaccine Sales by Country (2024-2034) & (K Units)
Table 97. Latin America Human Genetically Engineered Vaccine Sales Market Share in Volume by Country (2024-2034)
Table 98. Latin America Human Genetically Engineered Vaccine Sales by Country (2024-2034) & (US$ Million)
Table 99. Latin America Human Genetically Engineered Vaccine Sales Market Share in Value by Country (2024-2034)
Table 100. Middle East and Africa Human Genetically Engineered Vaccine Sales by Country (2024-2024) & (K Units)
Table 101. Middle East and Africa Human Genetically Engineered Vaccine Sales Market Share in Volume by Country (2024-2024)
Table 102. Middle East and Africa Human Genetically Engineered Vaccine Sales by Country (2024-2024) & (US$ Million)
Table 103. Middle East and Africa Human Genetically Engineered Vaccine Sales Market Share in Value by Country (2024-2024)
Table 104. Middle East and Africa Human Genetically Engineered Vaccine Sales by Country (2024-2034) & (K Units)
Table 105. Middle East and Africa Human Genetically Engineered Vaccine Sales Market Share in Volume by Country (2024-2034)
Table 106. Middle East and Africa Human Genetically Engineered Vaccine Sales by Country (2024-2034) & (US$ Million)
Table 107. Middle East and Africa Human Genetically Engineered Vaccine Sales Market Share in Value by Country (2024-2034)
Table 108. Pfizer Company Information
Table 109. Pfizer Introduction and Business Overview
Table 110. Pfizer Human Genetically Engineered Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 111. Pfizer Human Genetically Engineered Vaccine Product
Table 112. Pfizer Recent Development
Table 113. Merck Company Information
Table 114. Merck Introduction and Business Overview
Table 115. Merck Human Genetically Engineered Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 116. Merck Human Genetically Engineered Vaccine Product
Table 117. Merck Recent Development
Table 118. GSK Company Information
Table 119. GSK Introduction and Business Overview
Table 120. GSK Human Genetically Engineered Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 121. GSK Human Genetically Engineered Vaccine Product
Table 122. GSK Recent Development
Table 123. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Company Information
Table 124. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Introduction and Business Overview
Table 125. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 126. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Product
Table 127. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Recent Development
Table 128. Walvax Biotechnology Co., Ltd. Company Information
Table 129. Walvax Biotechnology Co., Ltd. Introduction and Business Overview
Table 130. Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 131. Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Product
Table 132. Walvax Biotechnology Co., Ltd. Recent Development
Table 133. Bharat Biotech Company Information
Table 134. Bharat Biotech Introduction and Business Overview
Table 135. Bharat Biotech Human Genetically Engineered Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 136. Bharat Biotech Human Genetically Engineered Vaccine Product
Table 137. Bharat Biotech Recent Development
Table 138. Chengdu Kanghua Biological Products Co., Ltd. Company Information
Table 139. Chengdu Kanghua Biological Products Co., Ltd. Introduction and Business Overview
Table 140. Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 141. Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Product
Table 142. Chengdu Kanghua Biological Products Co., Ltd. Recent Development
Table 143. South China Vaccine Corporation Limited Company Information
Table 144. South China Vaccine Corporation Limited Introduction and Business Overview
Table 145. South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 146. South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Product
Table 147. South China Vaccine Corporation Limited Recent Development
Table 148. Beijing Health Guard Biotechnology Inc. Company Information
Table 149. Beijing Health Guard Biotechnology Inc. Introduction and Business Overview
Table 150. Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 151. Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Product
Table 152. Beijing Health Guard Biotechnology Inc. Recent Development
Table 153. CSL Limited Company Information
Table 154. CSL Limited Introduction and Business Overview
Table 155. CSL Limited Human Genetically Engineered Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 156. CSL Limited Human Genetically Engineered Vaccine Product
Table 157. CSL Limited Recent Development
Table 158. Emergent BioSolutions Company Information
Table 159. Emergent BioSolutions Introduction and Business Overview
Table 160. Emergent BioSolutions Human Genetically Engineered Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 161. Emergent BioSolutions Human Genetically Engineered Vaccine Product
Table 162. Emergent BioSolutions Recent Development
Table 163. Sanofi Pasteur Company Information
Table 164. Sanofi Pasteur Introduction and Business Overview
Table 165. Sanofi Pasteur Human Genetically Engineered Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 166. Sanofi Pasteur Human Genetically Engineered Vaccine Product
Table 167. Sanofi Pasteur Recent Development
Table 168. Serum Institute Company Information
Table 169. Serum Institute Introduction and Business Overview
Table 170. Serum Institute Human Genetically Engineered Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 171. Serum Institute Human Genetically Engineered Vaccine Product
Table 172. Serum Institute Recent Development
Table 173. Key Raw Materials Lists
Table 174. Raw Materials Key Suppliers Lists
Table 175. Human Genetically Engineered Vaccine Market Trends
Table 176. Human Genetically Engineered Vaccine Market Drivers
Table 177. Human Genetically Engineered Vaccine Market Challenges
Table 178. Human Genetically Engineered Vaccine Market Restraints
Table 179. Human Genetically Engineered Vaccine Distributors List
Table 180. Human Genetically Engineered Vaccine Downstream Customers
Table 181. Research Programs/Design for This Report
Table 182. Key Data Information from Secondary Sources
Table 183. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Genetically Engineered Vaccine Product Picture
Figure 2. Global Human Genetically Engineered Vaccine Market Size, 2024 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Human Genetically Engineered Vaccine Market Size Status and Outlook (2024-2034) & (US$ Million)
Figure 4. Global Human Genetically Engineered Vaccine Sales Status and Outlook (2024-2034) & (K Units)
Figure 5. Product Picture of Genetic Recombinant Vaccine
Figure 6. Global Genetic Recombinant Vaccine Sales YoY Growth (2024-2034) & (K Units)
Figure 7. Product Picture of Recombinant Subunit Vaccines
Figure 8. Global Recombinant Subunit Vaccines Sales YoY Growth (2024-2034) & (K Units)
Figure 9. Product Picture of Genetic Vaccine
Figure 10. Global Genetic Vaccine Sales YoY Growth (2024-2034) & (K Units)
Figure 11. Global Human Genetically Engineered Vaccine Sales by Type (2024-2034) & (US$ Million)
Figure 12. Global Human Genetically Engineered Vaccine Sales Market Share by Type in 2022 & 2034
Figure 13. North America Human Genetically Engineered Vaccine Sales Market Share in Volume by Type in 2022
Figure 14. North America Human Genetically Engineered Vaccine Sales Market Share in Value by Type in 2022
Figure 15. Europe Human Genetically Engineered Vaccine Sales Market Share in Volume by Type in 2022
Figure 16. Europe Human Genetically Engineered Vaccine Sales Market Share in Value by Type in 2022
Figure 17. Asia-Pacific Human Genetically Engineered Vaccine Sales Market Share in Volume by Type in 2022
Figure 18. Asia-Pacific Human Genetically Engineered Vaccine Sales Market Share in Value by Type in 2022
Figure 19. Latin America Human Genetically Engineered Vaccine Sales Market Share in Volume by Type in 2022
Figure 20. Latin America Human Genetically Engineered Vaccine Sales Market Share in Value by Type in 2022
Figure 21. Middle East and Africa Human Genetically Engineered Vaccine Sales Market Share in Volume by Type in 2022
Figure 22. Middle East and Africa Human Genetically Engineered Vaccine Sales Market Share in Value by Type in 2022
Figure 23. The 5 and 10 Largest Manufacturers in the World: Market Share by Human Genetically Engineered Vaccine Sales in 2022
Figure 24. The 5 and 10 Largest Manufacturers in the World: Market Share by Human Genetically Engineered Vaccine Revenue in 2022
Figure 25. Human Genetically Engineered Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2024 VS 2022
Figure 26. Product Picture of Hepatitis E
Figure 27. Global Hepatitis E Sales YoY Growth (2024-2034) & (K Units)
Figure 28. Product Picture of Human Papillomavirus (HPV)
Figure 29. Global Human Papillomavirus (HPV) Sales YoY Growth (2024-2034) & (K Units)
Figure 30. Product Picture of Rotavirus
Figure 31. Global Rotavirus Sales YoY Growth (2024-2034) & (K Units)
Figure 32. Product Picture of Others
Figure 33. Global Others Sales YoY Growth (2024-2034) & (K Units)
Figure 34. Global Human Genetically Engineered Vaccine Sales by Application (2024-2034) & (US$ Million)
Figure 35. Global Human Genetically Engineered Vaccine Sales Market Share by Application in 2022 & 2034
Figure 36. North America Human Genetically Engineered Vaccine Sales Market Share in Volume by Application in 2022
Figure 37. North America Human Genetically Engineered Vaccine Sales Market Share in Value by Application in 2022
Figure 38. Europe Human Genetically Engineered Vaccine Sales Market Share in Volume by Application in 2022
Figure 39. Europe Human Genetically Engineered Vaccine Sales Market Share in Value by Application in 2022
Figure 40. Asia-Pacific Human Genetically Engineered Vaccine Sales Market Share in Volume by Application in 2022
Figure 41. Asia-Pacific Human Genetically Engineered Vaccine Sales Market Share in Value by Application in 2022
Figure 42. Latin America Human Genetically Engineered Vaccine Sales Market Share in Volume by Application in 2022
Figure 43. Latin America Human Genetically Engineered Vaccine Sales Market Share in Value by Application in 2022
Figure 44. Middle East and Africa Human Genetically Engineered Vaccine Sales Market Share in Value by Application in 2022
Figure 45. Key Raw Materials Price
Figure 46. Human Genetically Engineered Vaccine Manufacturing Cost Structure
Figure 47. Human Genetically Engineered Vaccine Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries